TWA
RYTM icon

TCI Wealth Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

TCI Wealth Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-254
Closed -$4.53K – 1841
2023
Q1 		$4.53K Buy
+254
New +$6.38K ﹤0.01% 1597
2022
Q2 		– Sell
-472
Closed -$5K – 2483
2022
Q1 		$5K Buy
+472
New +$4.14K ﹤0.01% 1592

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

TCI Wealth Advisors's RYTM Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2023, closing a stake of 254 shares — an estimated $4.53K sold.

TCI Wealth Advisors first reported a position in RYTM in Q1 2022 and held it in 2 quarters. The position peaked at $5K in Q1 2022. 116 funds tracked by Wall St. Rank hold RYTM as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 254 Rhythm Pharmaceuticals shares in Q2 2023, an estimated $4.53K.
  • TCI Wealth Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • TCI Wealth Advisors's Rhythm Pharmaceuticals position peaked at $5K in Q1 2022.
  • 116 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.